PL398781A1 - Sposoby i zestawy do prognozowania ryzyka wystapienia reakcji na wlew oraz zaniku odpowiedzi której posrednicza przeciwciala poprzez monitorowanie kwasu moczowego w surowicy podczas terapii z zastosowaniem pegylowanej urykazy - Google Patents

Sposoby i zestawy do prognozowania ryzyka wystapienia reakcji na wlew oraz zaniku odpowiedzi której posrednicza przeciwciala poprzez monitorowanie kwasu moczowego w surowicy podczas terapii z zastosowaniem pegylowanej urykazy

Info

Publication number
PL398781A1
PL398781A1 PL398781A PL39878110A PL398781A1 PL 398781 A1 PL398781 A1 PL 398781A1 PL 398781 A PL398781 A PL 398781A PL 39878110 A PL39878110 A PL 39878110A PL 398781 A1 PL398781 A1 PL 398781A1
Authority
PL
Poland
Prior art keywords
kits
predicting
developing
risk
loss
Prior art date
Application number
PL398781A
Other languages
English (en)
Inventor
Theresa Rosario-Jansen
David Erick Wright
Original Assignee
Savient Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Savient Pharmaceuticals, Inc. filed Critical Savient Pharmaceuticals, Inc.
Publication of PL398781A1 publication Critical patent/PL398781A1/pl

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/168—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y107/00—Oxidoreductases acting on other nitrogenous compounds as donors (1.7)
    • C12Y107/03—Oxidoreductases acting on other nitrogenous compounds as donors (1.7) with oxygen as acceptor (1.7.3)
    • C12Y107/03003—Factor-independent urate hydroxylase (1.7.3.3), i.e. uricase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/96—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood or serum control standard
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/906—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7)
    • G01N2333/90688—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7) acting on other nitrogen compounds as donors (1.7)
    • G01N2333/90694—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7) acting on other nitrogen compounds as donors (1.7) with oxygen as acceptor (1.7.3), e.g. uricase (1.7.3.3)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/107—Crystal induced conditions; Gout
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Wood Science & Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
PL398781A 2009-06-25 2010-06-25 Sposoby i zestawy do prognozowania ryzyka wystapienia reakcji na wlew oraz zaniku odpowiedzi której posrednicza przeciwciala poprzez monitorowanie kwasu moczowego w surowicy podczas terapii z zastosowaniem pegylowanej urykazy PL398781A1 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26966909P 2009-06-25 2009-06-25
US24869809P 2009-10-05 2009-10-05
US29871810P 2010-01-27 2010-01-27

Publications (1)

Publication Number Publication Date
PL398781A1 true PL398781A1 (pl) 2012-11-19

Family

ID=43386920

Family Applications (2)

Application Number Title Priority Date Filing Date
PL18214393.3T PL3482768T3 (pl) 2009-06-25 2010-06-25 Sposoby i zestawy do zapobiegania ryzyka reakcji na infuzję oraz utracie odpowiedzi spowodowanej przez przeciwciała poprzez monitorowanie stężenia kwasu moczowego w surowicy podczas terapii pegylowaną urykazą
PL398781A PL398781A1 (pl) 2009-06-25 2010-06-25 Sposoby i zestawy do prognozowania ryzyka wystapienia reakcji na wlew oraz zaniku odpowiedzi której posrednicza przeciwciala poprzez monitorowanie kwasu moczowego w surowicy podczas terapii z zastosowaniem pegylowanej urykazy

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL18214393.3T PL3482768T3 (pl) 2009-06-25 2010-06-25 Sposoby i zestawy do zapobiegania ryzyka reakcji na infuzję oraz utracie odpowiedzi spowodowanej przez przeciwciała poprzez monitorowanie stężenia kwasu moczowego w surowicy podczas terapii pegylowaną urykazą

Country Status (25)

Country Link
US (11) US9377454B2 (pl)
EP (3) EP4635567A3 (pl)
JP (2) JP2012531596A (pl)
KR (1) KR101861547B1 (pl)
CN (1) CN102803954A (pl)
AU (1) AU2010265964B2 (pl)
BR (1) BRPI1010069A2 (pl)
CA (1) CA2766309A1 (pl)
CZ (1) CZ2011827A3 (pl)
DK (1) DK3482768T3 (pl)
ES (1) ES3066542T3 (pl)
FI (1) FI3482768T3 (pl)
HR (1) HRP20260434T1 (pl)
HU (1) HUP1200205A3 (pl)
IL (1) IL216956A (pl)
LT (1) LT3482768T (pl)
MX (1) MX347903B (pl)
NZ (1) NZ597089A (pl)
PL (2) PL3482768T3 (pl)
PT (1) PT3482768T (pl)
RU (1) RU2535038C2 (pl)
SG (2) SG176897A1 (pl)
SI (1) SI3482768T1 (pl)
SM (1) SMT202600157T1 (pl)
WO (1) WO2010151823A1 (pl)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE298251T1 (de) 1998-08-06 2005-07-15 Mountain View Pharmaceuticals Peg-uricase konjugate und verwendung davon
KR20080009111A (ko) 2005-04-11 2008-01-24 새비언트 파마수티컬즈 인크. 유레이트 옥시다아제의 변이형 및 이의 용도
JP2012531596A (ja) 2009-06-25 2012-12-10 サヴィエント・ファーマシューティカルズ・インコーポレイテッド Ｐｅｇ化ウリカーゼ療法における血清尿酸をモニタリングすることにより注入反応の危険性および抗体媒介性効果消失を予測するための方法およびキット
CN107320734A (zh) 2011-04-29 2017-11-07 西莱克塔生物科技公司 从合成纳米载体中控制释放免疫抑制剂
CN105307641A (zh) 2013-05-03 2016-02-03 西莱克塔生物科技公司 用于降低不期望体液免疫应答的给药组合
CA3042642A1 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
DK3169315T3 (da) 2014-07-17 2020-08-10 Pharmaceutical Manufacturing Res Services In Væskefyldt doseringsform til forhindring af misbrug med øjeblikkelig frigivelse
EA201790551A1 (ru) 2014-09-07 2017-07-31 Селекта Байосайенсиз, Инк. Способы и композиции для ослабления иммунных ответов к пропускающему экзон вирусному трансферному вектору
AU2015336065A1 (en) 2014-10-20 2017-05-04 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
WO2016187026A1 (en) 2015-05-15 2016-11-24 Medimmune, Llc Improved uricase sequences and methods of treatment
CN116637177A (zh) 2016-11-11 2023-08-25 好利恩治疗美国公司 泼尼松和尿酸酶分子的组合疗法及其用途
EP4599848A3 (en) 2017-03-11 2025-12-03 Cartesian Therapeutics, Inc. Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
CN111373034A (zh) 2017-07-07 2020-07-03 艾乐娜制药有限公司 重组尿酸酶
US12121566B2 (en) 2019-01-30 2024-10-22 Horizon Therapeutics Usa, Inc. Methods for treating gout
WO2020160325A1 (en) * 2019-01-30 2020-08-06 Horizon Pharma Rheumatology Llc Reducing immunogenicity to pegloticase
WO2020160324A1 (en) * 2019-01-30 2020-08-06 Horizon Pharma Rheumatology Llc Reducing immunogenicity to pegloticase
US12553041B2 (en) 2019-06-04 2026-02-17 Cartesian Therapeutics Inc. Formulations and doses of pegylated uricase
EP4021482B1 (en) * 2019-08-30 2026-07-08 Horizon Therapeutics Ireland DAC Pegloticase for treatment of gout in renal transplant recipients
WO2021234676A1 (en) 2020-05-22 2021-11-25 Aab Therapeutics, Llc Compounds and methods for suppressing an immune response to substances containing polyethylene glycol
AU2021324665A1 (en) 2020-08-10 2023-04-13 Horizon Therapeutics Usa, Inc. Methods of treating gout
US12269875B2 (en) 2023-08-03 2025-04-08 Jeff R. Peterson Gout flare prevention methods using IL-1BETA blockers

Family Cites Families (168)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE279486C (pl)
DE279489C (pl)
US1016095A (en) 1910-09-08 1912-01-30 Gen Electric Splicing-sleeve.
US1141973A (en) 1911-05-22 1915-06-08 Jesse W Nichols Can-cap with vent-shield.
DE837379C (de) 1950-04-20 1955-08-16 Nordwind G M B H Windkraftanlage, insbesondere zum Antrieb einer Kolbenpumpe
US3451996A (en) 1968-02-12 1969-06-24 Thompson Farms Co Method for the preparation of heparin
US3616231A (en) 1968-11-14 1971-10-26 Boehringer Mannheim Gmbh Process for the production of uricase
US3613231A (en) 1969-07-25 1971-10-19 Paul F Pugh Method for manufacturing high voltage cable systems
US3931399A (en) 1970-12-22 1976-01-06 Behringwerke Aktiengesellschaft Process for isolating a fibrin-stabilizing factor
AU461334B2 (en) 1971-04-05 1975-05-22 Rca Ogrforaxicn Radiofrequency transistor structure and method for making
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4027676A (en) 1975-01-07 1977-06-07 Ethicon, Inc. Coated sutures
US4169764A (en) 1975-08-13 1979-10-02 Ajinomoto Co., Inc. Process for production of urokinase
US4141973A (en) 1975-10-17 1979-02-27 Biotrics, Inc. Ultrapure hyaluronic acid and the use thereof
US4064010A (en) 1976-07-21 1977-12-20 Eastman Kodak Company Purification of uricase
US4301153A (en) 1977-03-21 1981-11-17 Riker Laboratories, Inc. Heparin preparation
US4312979A (en) 1978-04-20 1982-01-26 Toyo Soda Manufacturing Co., Ltd. Polysaccharides containing allose
US4425431A (en) 1978-04-20 1984-01-10 Toyo Soda Manufacturing Co., Ltd. Production of an allose-containing polysaccharide
JPS6031472B2 (ja) 1978-12-14 1985-07-22 協和醗酵工業株式会社 酸性ウリカ−ゼ
US4251431A (en) 1979-01-16 1981-02-17 Shell Oil Company Lubricating greases
JPS5599189A (en) 1979-01-22 1980-07-28 Mihama Hisaharu Modified uricase free from antigenicity and its preparation
JPS55135590A (en) 1979-04-05 1980-10-22 Mihama Hisaharu Modified asparaginase and uricase and their preparation
DE2916711A1 (de) 1979-04-25 1980-11-06 Behringwerke Ag Blutgerinnungsfaktoren und verfahren zu ihrer herstellung
DE2943016C2 (de) 1979-10-24 1984-09-06 Dr. Rentschler Arzneimittel Gmbh & Co, 7958 Laupheim Verfahren zur Reinigung von Interferon
JPS5651995A (en) 1979-10-05 1981-05-09 Green Cross Corp:The Preparation of interferon
AU538665B2 (en) 1979-10-30 1984-08-23 Juridical Foundation, Japanese Foundation For Cancer Research Human interferon dna
DE3005897A1 (de) 1980-02-16 1981-09-03 Hoechst Ag, 6000 Frankfurt Genprodukt eines hoeheren organismus aus einem dieses gen enhtaltenden mikroorganismus
FR2475900A1 (fr) 1980-02-20 1981-08-21 Fabre Sa Pierre Complexe vaccinal contenant un antigene specifique et vaccin le contenant
CH651308A5 (de) 1980-07-01 1985-09-13 Hoffmann La Roche Interferone und deren herstellung.
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
JPS5740503A (en) 1980-08-22 1982-03-06 Seikagaku Kogyo Co Ltd Separation of saccharides
US4315852A (en) 1980-11-26 1982-02-16 Schering Corporation Extraction of interferon from bacteria
FR2497006A1 (fr) 1980-12-24 1982-06-25 Ind Electro Ste Gle Contacts electriques pour cables coaxiaux et cables bifilaires
JPS57192435A (en) 1981-05-20 1982-11-26 Toyobo Co Ltd Modified polypeptide
DE3126759A1 (de) 1981-07-07 1983-01-27 Boehringer Mannheim Gmbh, 6800 Mannheim Loesliche leber-uricase, verfahren zu ihrer herstellung und verwendung
US4450103A (en) 1982-03-01 1984-05-22 Cetus Corporation Process for recovering human IFN-β from a transformed microorganism
US4485176A (en) 1982-06-28 1984-11-27 E. I. Du Pont De Nemours & Company Turbidimetric method for measuring protein in urine and cerebrospinal fluid
EP0109688A3 (en) 1982-11-23 1986-12-03 The Wellcome Foundation Limited Improved complexes, processes for obtaining them and formulations containing such complexes
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
USD279486S (en) 1983-04-25 1985-07-02 International Jensen Incorporated Controller for a video game or the like
US4732863A (en) 1984-12-31 1988-03-22 University Of New Mexico PEG-modified antibody with reduced affinity for cell surface Fc receptors
JPH0671425B2 (ja) 1985-06-05 1994-09-14 サッポロビール株式会社 ウリカ−ゼおよびその製造法
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
EP0229108B1 (en) 1985-06-26 1990-12-27 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4847079A (en) 1985-07-29 1989-07-11 Schering Corporation Biologically stable interferon compositions comprising thimerosal
AU597924B2 (en) 1985-12-11 1990-06-14 Natinco Nv Solubilization of protein aggregates
DD279486A1 (de) 1986-03-10 1990-06-06 Akad Wissenschaften Ddr Verfahren zur aktivierung von hydroxylgruppenhaltigen polymeren verbindungen
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
JPS6255079A (ja) 1986-04-23 1987-03-10 Mihama Hisaharu 修飾ウリカ−ゼ
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
DD279489A1 (de) 1986-12-11 1990-06-06 Leuna Werke Veb Verfahren zur herstellung optisch transparenter epoxidharzformmassen
JPS63203548A (ja) 1987-02-12 1988-08-23 四国化工機株式会社 飲料用密封容器の製造装置
AU612133B2 (en) 1987-02-20 1991-07-04 Natinco Nv Production of proteins in active forms
CA1305285C (en) 1987-04-21 1992-07-14 Malcolm Roy Brandon Production of proteins in active forms
AU609824B2 (en) 1987-06-15 1991-05-09 Southern Cross Biotech Pty Ltd. Production of proteins in active forms
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
CA1286591C (en) 1987-12-18 1991-07-23 Douglas B. Taylor Apparatus for opening and closing roll-up door
US4847325A (en) 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
JPH01216939A (ja) 1988-02-24 1989-08-30 Hoechst Japan Kk 末熟児頭蓋内出血阻止剤
US4945086A (en) 1988-05-03 1990-07-31 The Board Of Trustees Of The Leland Stanford Junior University Smooth muscle cell growth inhibitor
US5955336A (en) 1988-08-17 1999-09-21 Toyo Boseki Kabushiki Kaisha DNA sequence for uricase and manufacturing process of uricase
GB8824591D0 (en) 1988-10-20 1988-11-23 Royal Free Hosp School Med Fractionation process
US5349052A (en) 1988-10-20 1994-09-20 Royal Free Hospital School Of Medicine Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
JP3148208B2 (ja) 1988-10-31 2001-03-19 富士ゼロックス株式会社 マルチ出力トレイ付プリントサーバおよびプリントシステム
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5324844A (en) 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5010183A (en) 1989-07-07 1991-04-23 Macfarlane Donald E Process for purifying DNA and RNA using cationic detergents
KR0159107B1 (ko) 1989-07-13 1998-11-16 쟝 르쌍드뢰 우레이트 산화효소 활성 단백질, 이 단백질을 암호화하는 재조합 유전자, 발현 벡터, 미생물 및 형질전환세포
NZ234453A (en) 1989-07-13 1993-01-27 Sanofi Sa Recombinant dna encoding urate oxidase, and vector, host, protein and pharmaceutical compositions associated therewith
JPH0354581A (ja) 1989-07-24 1991-03-08 Nec Corp 電子写真系プリンタの現像カートリッジ
US5286637A (en) 1989-08-07 1994-02-15 Debiopharm, S.A. Biologically active drug polymer derivatives and method for preparing same
KR927003090A (ko) 1989-08-23 1992-12-17 하다사 메디칼 오르가니제이션 헤파린효소를 포함하는 상처 치유 약제
JPH03148298A (ja) 1989-11-01 1991-06-25 Sumitomo Pharmaceut Co Ltd 修飾ペプチドおよびその製造方法
US5766897A (en) 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US5653974A (en) 1990-10-18 1997-08-05 Board Of Regents,The University Of Texas System Preparation and characterization of liposomal formulations of tumor necrosis factor
AU1674292A (en) 1991-03-15 1992-10-21 Synergen, Inc. Pegylation of polypeptides
ES2141108T3 (es) 1991-07-02 2000-03-16 Inhale Inc Metodo y dispositivo para proporcionar medicamentos en aerosol.
YU66892A (sh) 1991-08-20 1995-10-24 Hoechst Ag. Fosfoinositolglikan - peptid sa delovanjem kao insulin
JP3148298B2 (ja) 1991-09-02 2001-03-19 帝人株式会社 軽量複合成形物の製造法
US5298643A (en) 1992-12-22 1994-03-29 Enzon, Inc. Aryl imidate activated polyalkylene oxides
US5321095A (en) 1993-02-02 1994-06-14 Enzon, Inc. Azlactone activated polyalkylene oxides
WO1994019007A1 (en) 1993-02-16 1994-09-01 Enzon, Inc. Ribosome inactivating protein compositions having reduced antigenicity
US6385312B1 (en) 1993-02-22 2002-05-07 Murex Securities, Ltd. Automatic routing and information system for telephonic services
JP3875730B2 (ja) 1993-02-22 2007-01-31 サノフィ・アベンティス株式会社 自己免疫疾患の予防治療剤
US5298410A (en) 1993-02-25 1994-03-29 Sterling Winthrop Inc. Lyophilized formulation of polyethylene oxide modified proteins with increased shelf-life
JPH06255079A (ja) 1993-03-08 1994-09-13 Akira Totsuka 被服地のスクリーン印刷装置及び被服地のスクリーン印刷方法
JPH08511157A (ja) 1993-04-09 1996-11-26 バイオ − テクノロジー・ジェネラル・コーポレーション Ｘａファクター阻害活性を有する新規ポリペプチド
US5863534A (en) 1993-04-09 1999-01-26 Bio-Technology General Corp. Polypeptide having factor Xa inhibitory method of reducing blood coagulation with a novel polypeptide having factor Xa inhibitory activity
AU6586394A (en) 1993-04-22 1994-11-08 Celtrix Pharmaceuticals, Inc. Conjugates of growth factor and bone resorption inhibitor
AU7113594A (en) 1993-06-21 1995-01-17 Enzon, Inc. Site specific synthesis of conjugated peptides
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
JPH09504174A (ja) 1993-10-29 1997-04-28 インサイト ファーマシューティカルズ，インク． プロテアーゼネキシン１変異体を含むキメラ蛋白
HUT75533A (en) 1993-11-10 1997-05-28 Schering Corp Improved interferon polymer conjugates
US5470306A (en) 1994-02-23 1995-11-28 Kirschner Medical Corporation Medical bandaging article and packaging system
US5656279A (en) 1994-02-23 1997-08-12 Bio Med Sciences, Inc. Semi-interpenetrating polymer network scar treatment sheeting, process of manufacture and useful articles thereof
US5795776A (en) 1994-03-22 1998-08-18 Bio-Technology General Corp. Expression plasmids regulated by an OSMB promoter
FI96317C (fi) 1994-05-31 1996-06-10 Exavena Oy Menetelmä hienojakoisten ja muunnettujen tärkkelyksien valmistamiseksi
DE4423131A1 (de) 1994-07-01 1996-01-04 Bayer Ag Neue hIL-4-Mutantenproteine als Antagonisten oder partielle Agonisten des humanen Interleukin 4
US5633227A (en) 1994-09-12 1997-05-27 Miles, Inc. Secretory leukocyte protease inhibitor as an inhibitor of tryptase
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
JPH10510516A (ja) 1994-12-07 1998-10-13 ノボ ノルディスク アクティーゼルスカブ アレルゲン性を減らしたポリペプチド
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
IL116696A (en) 1995-01-25 1999-08-17 Bio Technology General Corp Production of enzymatically active recombinant carboxypeptidase b
TW426523B (en) 1995-04-06 2001-03-21 Hoffmann La Roche Interferon solution
FR2733914B1 (fr) 1995-05-11 1997-08-01 Sanofi Sa Composition de liquide stable contenant de l'urate oxydase et composition lyophilisee pour sa preparation
JPH09154581A (ja) 1995-12-05 1997-06-17 Asahi Chem Ind Co Ltd ウリカーゼを生産する実質上純粋な微生物
US6006753A (en) 1996-08-30 1999-12-28 Eli Lilly And Company Use of GLP-1 or analogs to abolish catabolic changes after surgery
DK1007082T3 (da) 1997-01-15 2007-02-19 Phoenix Pharmacologics Inc Modificeret tumor nekrose faktor
US5816397A (en) 1997-01-21 1998-10-06 Ogio International, Inc. Golf club carrying apparatus
AU740207B2 (en) 1997-02-06 2001-11-01 Novozymes A/S Polypeptide-polymer conjugates having added and/or removed attachment groups
KR100369838B1 (ko) 1997-02-26 2003-09-29 주식회사 엘지생명과학 한국형c형간염바이러스의비구조단백질3에서유래한단백질분해효소단백질및그의제조방법
US6821763B2 (en) 1997-07-04 2004-11-23 Ajinomoto Co., Inc. Process for producing microbial transglutaminase
JPH1175876A (ja) 1997-07-04 1999-03-23 Ajinomoto Co Inc 新規な微生物トランスグルタミナーゼの製造法
ES2228052T3 (es) 1998-06-01 2005-04-01 Genentech, Inc. Separacion demonomeros de anticuerpos de sus multimeros utilizando cromatografia de intercambio de iones.
US6783965B1 (en) 2000-02-10 2004-08-31 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
US20060188971A1 (en) 1998-08-06 2006-08-24 Duke University Urate oxidase
US7056713B1 (en) 1998-08-06 2006-06-06 Duke University Urate oxidase
ATE298251T1 (de) 1998-08-06 2005-07-15 Mountain View Pharmaceuticals Peg-uricase konjugate und verwendung davon
PL202799B1 (pl) 1998-08-06 2009-07-31 Mountain View Pharmaceuticals Sposób izolowania urykazy w postaci tetramerycznej oraz wyizolowana tetrameryczna urykaza
US6425448B1 (en) 2001-01-30 2002-07-30 Cdx Gas, L.L.P. Method and system for accessing subterranean zones from a limited surface area
US6429860B1 (en) 1999-06-15 2002-08-06 Visicomp, Inc. Method and system for run-time visualization of the function and operation of a computer program
IL151030A0 (en) 2000-02-14 2003-04-10 First Opinion Corp Automated diagnostic system and method
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
US20050084478A1 (en) 2000-10-17 2005-04-21 Chih-Ping Liu Combination therapy using interferon-tau
NZ528076A (en) 2001-03-02 2005-09-30 Medimmune Inc Methods of preventing or treating inflammatory or autoimmune disorders by administering integrin alphav beta3 antagonists with an immunomodulatory agents, anti-inflammatory agents, TNF-alpha antagonists or CD2 binding molecules
US6913915B2 (en) 2001-08-02 2005-07-05 Phoenix Pharmacologics, Inc. PEG-modified uricase
KR20030043780A (ko) 2001-11-28 2003-06-02 주식회사 바이오폴리메드 생체적합성 비항원성 공중합체와 그 결합체 및 이들의제조방법
NZ540895A (en) 2003-01-09 2007-03-30 Genentech Inc Purification of polypeptides with ethacridine lactate
JP4273998B2 (ja) 2004-02-26 2009-06-03 学校法人東海大学 プロテオーム解析用試料の調製方法
US20050282877A1 (en) 2004-04-13 2005-12-22 Becker Bryan N Method of decreasing inflammation in kidney transplantion using angiotensin receptor blockers
CN103088038B (zh) 2004-07-12 2015-06-24 美国天甲生物医药有限公司 黄病毒疫苗
GB0420888D0 (en) 2004-09-20 2004-10-20 Photopharmica Ltd Compounds and uses
MX2007012548A (es) 2005-04-11 2008-03-11 Savient Pharmaceuticals Inc Formas variantes de urato oxidasa y uso de las mismas.
US8148123B2 (en) * 2005-04-11 2012-04-03 Savient Pharmaceuticals, Inc. Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
US20080159976A1 (en) 2005-04-11 2008-07-03 Jacob Hartman Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
KR20080009111A (ko) 2005-04-11 2008-01-24 새비언트 파마수티컬즈 인크. 유레이트 옥시다아제의 변이형 및 이의 용도
MX2008010806A (es) 2006-02-22 2008-09-01 Novartis Pharma Ag Sistema para la administracion de ciclosporina nebulizada y metodos de tratamiento.
KR101288027B1 (ko) 2006-04-12 2013-07-22 새비언트 파마수티컬즈 인크. 양이온 계면활성제를 이용한 단백질 정제 방법
NL1031926C2 (nl) 2006-05-31 2007-12-03 X Flow Bv Inrichting met een bioreactor en membraanfiltratiemodule voor het behandelen van een inkomend fluïdum.
CN100558403C (zh) 2006-10-23 2009-11-11 中国科学院理化技术研究所 双壳层药物缓控释载体材料及其制备方法和用途
US20080145876A1 (en) 2006-11-21 2008-06-19 University Of Southern California Poly(ethylene glycol) anti-body detection assays and kits for performing thereof
CN101168052A (zh) 2007-10-26 2008-04-30 西安交通大学 一种防治高尿酸血症及痛风的肠溶制剂
FR2924271B1 (fr) 2007-11-27 2010-09-03 Picogiga Internat Dispositif electronique a champ electrique controle
CA2737163C (en) 2008-09-15 2019-03-12 Elan Pharmaceuticals, Inc. Methods of treatment of hyperuricemia and associated disease states
US20100160351A1 (en) 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Pharmaceutical compositions and methods for treating hyperuricemia and related disorders
WO2010071865A1 (en) 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Pharmaceutical compositions and methods for treating hyperuricemia and related disorders
SG176896A1 (en) 2009-06-25 2012-01-30 Savient Pharmaceuticals Inc Methods for assessing tophus response during urate lowering therapy in treatment tophaceous gout
JP2012531596A (ja) 2009-06-25 2012-12-10 サヴィエント・ファーマシューティカルズ・インコーポレイテッド Ｐｅｇ化ウリカーゼ療法における血清尿酸をモニタリングすることにより注入反応の危険性および抗体媒介性効果消失を予測するための方法およびキット
WO2011032175A1 (en) 2009-09-14 2011-03-17 Nuon Therapeutics, Inc. Combination formulations of tranilast and allopurinol and methods related thereto
JP5451464B2 (ja) 2010-03-09 2014-03-26 キヤノン株式会社 帯電装置
EP2560642A4 (en) 2010-03-30 2013-12-18 Ardea Biosciences Inc TREATMENT OF GICHT
MX357510B (es) 2011-11-04 2018-07-12 Cymabay Therapeutics Inc Metodos para tratar ataques de gota.
JP5888130B2 (ja) 2012-06-06 2016-03-16 富士通株式会社 通信端末装置および通信制御方法
JP5746101B2 (ja) 2012-06-18 2015-07-08 コスメディ製薬株式会社 マイクロニードルの迅速溶解法
GB2512876A (en) 2013-04-09 2014-10-15 Image Analysis Ltd Methods and apparatus for quantifying inflammation
PL3536685T3 (pl) 2014-04-04 2022-05-16 Pfizer Inc. Bicykliczne skondensowane związki heteroarylowe lub arylowe i ich zastosowanie jako inhibitory IRAK4
RS65941B1 (sr) 2016-03-11 2024-10-31 Cartesian Therapeutics Inc Formulacije i doze pegilovane urikaze
US20180008665A1 (en) 2016-07-05 2018-01-11 CanTrust LifeScience Corp. Methods of treating and preventing gout and lead nephropathy
CN116637177A (zh) 2016-11-11 2023-08-25 好利恩治疗美国公司 泼尼松和尿酸酶分子的组合疗法及其用途
EP4599848A3 (en) 2017-03-11 2025-12-03 Cartesian Therapeutics, Inc. Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
WO2020160324A1 (en) 2019-01-30 2020-08-06 Horizon Pharma Rheumatology Llc Reducing immunogenicity to pegloticase
WO2020160325A1 (en) 2019-01-30 2020-08-06 Horizon Pharma Rheumatology Llc Reducing immunogenicity to pegloticase
US12121566B2 (en) 2019-01-30 2024-10-22 Horizon Therapeutics Usa, Inc. Methods for treating gout
EP4021482B1 (en) 2019-08-30 2026-07-08 Horizon Therapeutics Ireland DAC Pegloticase for treatment of gout in renal transplant recipients
AU2021324665A1 (en) 2020-08-10 2023-04-13 Horizon Therapeutics Usa, Inc. Methods of treating gout

Also Published As

Publication number Publication date
RU2535038C2 (ru) 2014-12-10
RU2012102399A (ru) 2013-07-27
BRPI1010069A2 (pt) 2016-03-15
HRP20260434T1 (hr) 2026-05-08
US20260023073A1 (en) 2026-01-22
MX347903B (es) 2017-05-18
CN102803954A (zh) 2012-11-28
US20120301454A1 (en) 2012-11-29
EP2446260A1 (en) 2012-05-02
US20230251247A1 (en) 2023-08-10
US20250231181A1 (en) 2025-07-17
JP2012531596A (ja) 2012-12-10
US12188927B2 (en) 2025-01-07
US20210181187A1 (en) 2021-06-17
DK3482768T3 (da) 2026-04-07
EP2446260B1 (en) 2018-12-26
US11982670B2 (en) 2024-05-14
AU2010265964B2 (en) 2014-09-18
PL3482768T3 (pl) 2026-07-20
SG10201408480RA (en) 2015-02-27
PT3482768T (pt) 2026-04-02
US20230028134A1 (en) 2023-01-26
SG176897A1 (en) 2012-01-30
US10823727B2 (en) 2020-11-03
AU2010265964A1 (en) 2012-02-02
US20160377604A1 (en) 2016-12-29
SI3482768T1 (sl) 2026-07-31
WO2010151823A1 (en) 2010-12-29
JP2015111137A (ja) 2015-06-18
IL216956A0 (en) 2012-02-29
IL216956A (en) 2016-10-31
US10139399B2 (en) 2018-11-27
LT3482768T (lt) 2026-04-27
FI3482768T3 (fi) 2026-03-27
CZ2011827A3 (cs) 2012-09-26
EP2446260A4 (en) 2013-11-20
US12560596B2 (en) 2026-02-24
EP4635567A3 (en) 2025-12-03
EP4635567A2 (en) 2025-10-22
US11598767B2 (en) 2023-03-07
US20240255496A1 (en) 2024-08-01
ES3066542T3 (en) 2026-05-13
US20190317083A1 (en) 2019-10-17
MX2011013489A (es) 2012-05-29
CA2766309A1 (en) 2010-12-29
US9377454B2 (en) 2016-06-28
HUP1200205A3 (en) 2012-09-28
NZ597089A (en) 2014-05-30
KR101861547B1 (ko) 2018-07-02
US20180188242A1 (en) 2018-07-05
EP3482768A1 (en) 2019-05-15
KR20120046125A (ko) 2012-05-09
US11639927B2 (en) 2023-05-02
EP3482768B1 (en) 2026-01-28
US12669498B2 (en) 2026-06-30
HUP1200205A2 (en) 2012-06-28
US20260118349A1 (en) 2026-04-30
SMT202600157T1 (it) 2026-05-12

Similar Documents

Publication Publication Date Title
ES3066542T3 (en) Methods and kits for preventing infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
ZA201102252B (en) Methods and kits for nucleic acid sequencing
LU91864B1 (en) Method and kit for the isolation of genomic DNA, RNA, proteins and metabolites from a single biological sample
HUE054639T2 (hu) Nukleinsav-szekvencia kiegyensúlyozatlanságának meghatározása
DK2885641T3 (da) Fremgangsmådeer til forudsigelse af risiko for udvikling af hypertension
EP2661494A4 (en) PROMOTERS, EXPRESSION CASSETTES, VECTORS, KITS AND METHODS FOR TREATING COLOR BLINDNESS AND OTHER PROBLEMS
IN2014CN04326A (pl)
WO2012076553A3 (en) Biomarkers and parameters for hypertensive disorders of pregnancy
HRP20150449T1 (xx) Metode lijeäśenja multiplog mijeloma primjenom kombiniranih terapija temeljenih na anti-cs1 antitijelima
WO2013066369A3 (en) Methods for detecting graft-versus-host disease
MX2012014284A (es) Metodos y kits para diagnosticar afecciones relacionadas con hipoxia.
WO2011149947A3 (en) Methods of determining amyloid beta turnover in blood
EP2254897A4 (en) METHOD, REAGENTS AND KITS FOR DETECTING NUCLEIC ACID MOLECULES
EP2504348A4 (en) METHODS, REAGENTS AND KITS FOR DETECTING NUCLEIC ACID MOLECULES
WO2011047058A3 (en) Assay for the prediction of therapeutic effectiveness of mesenchymal stromal cells, and methods of using same
EE201000069A (et) Meetod ja elektrolser desinfitseeriva vahendi saamiseks
WO2011067711A3 (en) Novel heparanase splice variant
EP2297325A4 (en) METHODS OF STRATIFICATION, PROGNOSIS AND DIAGNOSIS OF SCHIZOPHRENIA, MUTANT NUCLEIC ACID MOLECULES AND POLYPEPTIDES
HK1206791A1 (en) Means and methods for response prediction of hepatitis b treatment
WO2012080721A3 (en) Plasma cell disorders
WO2009151337A3 (en) Novel retinoid inducible factor and uses thereof
NO20071496L (no) Elektrolytt og fremgangsmate for elektrokjemisk raffinering av silisium
EP2739733A4 (en) NUCLEIC ACID COMPOUNDS, PROCESSES AND KITS FOR FAST PAIRING OF AFFINITY MATERIALS
WO2012128799A3 (en) Treating schizophrenia
WO2011041725A3 (en) Schizophrenia treatment response biomarkers